Affiliation:
1. Department of Chemistry, Biochemistry and Environmental Protection, Faculty of Sciences, University of Novi Sad, Trg Dositeja Obradovica 3, 21000 Novi Sad, Serbia
Abstract
Testolactone is structurally related to testosterone and belongs to the first generation of aromatase inhibitors. It is a non-selective irreversible aromatase enzyme inhibitor that was one of the first steroids used in the clinical treatment of breast cancer. The use of testolactone in the treatment of breast cancer started in 1970, although its ability to inhibit aromatase was not discovered until 1975. Its use was primarily based on the inhibition of estrogen synthesis, which was applied in the treatment of estrogen-dependent breast cancers, in the treatment of disorders of sex steroid excess, familial male-limited precocious puberty, or in the treatment of patients with McCune–Albright syndrome, etc. The weak inhibitory activity of testolactone, and the moderate clinical response, prevented its widespread use, which ultimately resulted in withdrawal from the drug market in 2008. This review paper is dedicated to testolactone, its rise in the second half of the 20th century, and its fall in the first decade of the 21st century. Regardless of withdrawal from the market, for many years testolactone was a drug that improved the quality of life of patients facing one of the most serious diseases today, and for this reason, this paper describes medicinal application, synthesis, and modifications of testolactone.
Funder
Ministry of Education, Science and Technological Development of the Republic of Serbia
Provincial Secretariat for Higher Education and Scientific Research of the Autonomous Province of Vojvodina
Reference140 articles.
1. Lemke, T.L., and Williams, D.A. (2012). Foye’s Principles of Medicinal Chemistry, Lippincott Williams & Wilkins. [7th ed.].
2. Studies of human placental aromatase;Siiteri;J. Steroid Biochem.,1975
3. Testolactone;Florey;Analytical Profiles of Drug Substances,1976
4. Aromatase inhibitors: Past, present and future in breast cancer therapy;Dutta;Med. Oncol.,2008
5. Aromatase inhibitors in early breast cancer therapy: A variety of treatment strategies;Dixon;Exp. Opin. Pharmacother.,2006
Cited by
5 articles.
订阅此论文施引文献
订阅此论文施引文献,注册后可以免费订阅5篇论文的施引文献,订阅后可以查看论文全部施引文献